Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mitsuko Asai is active.

Publication


Featured researches published by Mitsuko Asai.


Nature | 1977

Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia

Eiji Higashide; Mitsuko Asai; Koichiro Ootsu; Seiich Tanida; Yoshio Kozai; Toru Hasegawa; Toyokazu Kishi; Yukio Sugino; Masahiko Yoneda

WE have isolated a new group of ansamycin antibiotics with potent antitumour activity, from a fermentation broth of Nocardia sp. No. C-15003 (N-l) and have named it ansamitocin. Structures of ansamitocin were found to be similar to maytansine and related maytansinoids obtained from plant sources by Kupchan et al.1–4 and Wani et al.5. These comounds have strong antitumour activities, but development of production would be difficult, because plants containing maytansinoids are only harvested in tropical areas and their content in the plants is extremely low. Some attempts have been made to find a maytansinoid-producing microorganism6, but no success has been reported. We report here the microbial production, isolation and structural elucidation of these antibiotics and their antitumour activities against several experimental tumours in mice.


Life Sciences | 1985

Emeriamine, an antidiabetic β-aminobetaine derived from a novel fungal metabolite

Tsuneo Kanamaru; Susumu Shinagawa; Mitsuko Asai; Hisayoshi Okazaki; Yasuo Sugiyama; Takeshi Fujita; Hisashi Iwatsuka; Masahiko Yoneda

Abstract Emeriamine [(R)-3-amino-4-trimethylaminobutyric acid], derived from a novel fungal metabolite “emericedin” [(R)-3-acetylamino-4-trimethylaminobutyric acid], was proved to be a strong and specific inhibitor of carnitine-dependent oxidation of long chain fatty acid (IC 50 ; 3.2 × 10 −6 M) and its main inhibition site was shown to be carnitine palmitoyltransferase I located on the outer-surface of the mitochondrial inner membrane. Emeriamine also showed hypoglycemic and antiketogenic activities in a dose-dependent manner (1–10 mg/kg) when administered orally to fasted normal and diabetic animals.


Tetrahedron | 1981

The structures of macbecin I and II : New antitumor antibiotics

Masayuki Muroi; Konomi Haibara; Mitsuko Asai; Kazuhide Kamiya; Toyokazu Kishi

Abstract Macbecin I 1 , C 30 H 42 N 2 O 8 , and macbecin II 2 , C 30 H 44 N 2 O 8 , were shown to be 2,6-disubstituted benzoquinone and hydroquinone derivatives by an oxidation-reduction relationship, UV. 1 H and 13 C NMR spectra. Alkaline methanolysis of 1 gave a 2-aminobenzoquinone derivative 5 , suggesting an ansa-structure for 1 , and acid hydrolysis of 1 gave decarbamoyl products 9 , 10 and 11 , indicative of the location of carbamoyloxy group in allylic position. Spin decoupling studies on 1 , 3 and 5 clarified the partial structures [ A ], [ B ], [ C ] and [ D ]. From their mutual disposition two structures 1a and 1b , were proposed out of which 1a has been selected for the structure of 1 on the basis of the structure of oxidative degradation product 12 . X-Ray analysis of the bromoacetyl derivative of 1 confirmed the above proposed structure and determined the absolute stereochemistry of 1 and 2 .


Tetrahedron | 1983

Stereo-chemical studies on the sulfoxide of 5,6-cis-carbapenem antibiotics, C-19393 components

Setsuo Harada; Shigetoshi Tsubotani; Susumu Shinagawa; Mitsuko Asai

Abstract The absolute configuration at the sulfoxide of 5,6- cis -carbapenem antibiotics is discussed on the basis of chemical reactions and the CD spectral data. Some stereoisomers at the side chain were synthesized from C-19393 H 2 by the combination of hydrogenation, oxidation and Z,E -isomerization. The CD spectral studies revealed that the Cotton effects of stereoisomers at the sulfoxide indicated clear opposite signs at both 260–275 and 280–300 nm regions. Further CD spectral studies on the derivatives elucidated that these Cotton effects may reflect two chromophores; for the former region and for the latter. In conclusion, these naturally occurring 5,6- cis -carbapenem antibiotics have been shown to possess the R -configuration at the sulfoxide.


Tetrahedron Letters | 1980

The structures of macbecin I and II, new antitumor antibiotics

Masayuki Muroi; Konomi Haibara; Mitsuko Asai; Toyokazu Kishi

Abstract Structures of macbecin I (1) and II (2), new antitumor antibiotics isolated from the culture broth of Nocardia sp. No. C-14919, have been elucidated as benzenoid ansamycins on the basis of chemical evidence and spectral analyses.


Cellular and Molecular Life Sciences | 1971

Opposite chirality of pillaromycin A to tetracyclines: the X-ray analysis of Achromycin hydrochloride.

Kazuhide Kamiya; Mitsuko Asai; Yoshikazu Wada; Masao Nishikawa

Durch Röntgen-Strukturanalyse wurde die absolute Konfiguration des Antibiotikums Achromycin ermittelt. Sie ist zu derjenigen des verwandten, aus Kulturen vonStreptomyces flavovirens stammenden Pillaromycins A entgegengesetzt.


Nature | 1981

Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin.

A. Imada; K. Kitano; K. Kintaka; M. Muroi; Mitsuko Asai


Archive | 1981

Fermentation process of preparing demethyl maytansinoids

Mitsuko Asai; Kazuo Nakahama; Motowo Izawa


Archive | 1980

20-O-Acylmaytansinoids

Mitsuko Asai


Archive | 1977

Method for producing maytansinol and its derivatives

Eiji Higashide; Mitsuko Asai; Seiichi Tanida

Collaboration


Dive into the Mitsuko Asai's collaboration.

Top Co-Authors

Avatar

Toyokazu Kishi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Masayuki Muroi

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Eiji Higashide

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Seiichi Tanida

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Komei Mizuno

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Setsuo Harada

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Toru Masuda

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Satoru Kuwada

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Motowo Izawa

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar

Susumu Shinagawa

Takeda Pharmaceutical Company

View shared research outputs
Researchain Logo
Decentralizing Knowledge